DEA Reschedules CBD-Based Drug to Schedule V
According to a report from CNBC.com (1), the U.S. Drug Enforcement Administration (DEA) has rescheduled GW Pharmaceuticals’ cannabidiol (CBD)-based drug, Epidiolex, to schedule V.
According to a report from CNBC.com (1), the U.S. Drug Enforcement Administration (DEA) has rescheduled GW Pharmaceuticals’ cannabidiol (CBD)-based drug, Epidiolex, to schedule V.
The U.S. Food and Drug Administration (FDA) approved Epidiolex in June 2018, as an oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy-Lennox-Gastaut syndrome and Dravet syndrome-in patients two years of age and older (2,3). The FDA’s approval of Epidiolex forced the DEA to consider how to classify it since cannabis is considered a schedule I drug, which is defined as having no currently accepted medical use and a high potential for abuse. Epidiolex will be classified as a schedule V controlled substance, which is the lowest level, defined as those with a proven medical use and low potential for abuse.
According to the CNBC report, the rescheduling applies to CBD containing no more than 0.1% tetrahydrocannabinol (THC), in FDA-approved drug products. This allows GW Pharmaceuticals to sell Epidiolex, but it does not broadly apply to all CBD products.
For more information on the descheduling, please read the full report from CNBC (1).
References:
- https://www.cnbc.com/2018/09/27/dea-schedules-epidiolex-allowing-gw-pharma-to-start-selling-the-drug.html
- https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm611046.htm?utm_campaign=06252018_PR_FDA%20approves%20marijuana-derived%20drug%20to%20treat%20two%20forms%20of%20epilepsy&utm_medium=email&utm_source=Eloqua
- http://www.cannabissciencetech.com/news/fda-approves-first-drug-containing-cbd
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
November 19th 2024A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.
